

Suppl. Table 1. Patient characteristics.

	Before treatment
Number of patients (n)	9
Male/Female	6/3
Mean age (years)	42.7 (30-64)
Ethnic background	
Caucasian	2
Turkish	6
Moroccan	1
Clinical manifestation (n /total n)	
Oral ulceration	7/9
Genital ulceration	6/9
Skin lesions	9/9
Arthralgia	8/9
Arthritis	3/9
Mean BCDAF at start \pm SD	5.4 \pm 1.4

The characteristics of 9 pre-treated patients with Behçet's disease before starting adalimumab.
N: number; SD: standard deviation.

Suppl. Table 2. Medication use of included patients treated with adalimumab.

Patient	1	2	3	4	5	6	7	8	9
Previous treatment*	D	Col P IFX	Cyc Pf P	Cut Opat	D Hcql SZP	Cut Col NSAID P	Col Hcql MTX P Pf	Th	SZP
Treatment start Ada	Col Cut SZP Th,	Cut Cyc NSAID SZP	Col Cut Myc NSAID SZP Th	Col NSAID P	Col Cut NSAID P	Col Cut NSAID	Col MTX, NSAID Th	Col Cut D Hcql NSAID P	Col Cut D Hcql NSAID P
Tapered**	SZP	Cyc SZP	Cut Myc NSAIDs	NSAID	Col NSAID	NSAID Col	Col MTX NSAIDs	Col D Hcql NSAID	NSAID
Stopped** < 6 months	Cut Th	Cut		P	Cut P	Cut	Th	Cyc	Cut D Hcql P
Stopped** > 6 months	Cut SZP Th	Cut Cyc	Myc SZP	P	Cut	Cut	MTX NSAIDs Th	Cyc	Cut D Hcql P

Prior, concomitant and tapered treatment in 9 patients with Behçet's disease, studied on the clinical effects of 40mg adalimumab subcutaneously every 2 weeks.

*Medication terminated > 1 months before inclusion.

**No new medication for symptoms of Behçet's disease were given.

Cut: cutaneous corticosteroids (including diprolene creme, triamcinolon paste and fluticasone creme); D: dapsone; Col: colchicine; SZP: sulfasalazine; Th: thalidomide; IFX: infliximab; Cyc: cyclosporine; NSAID: non steroidal anti-inflammatory drugs (including diclofenac, celecoxib, etoricoxib, indometacin and arthrotec); P: prednisone; Pf: Pentoxifylline; Myc: mycophenolic acid; Opat: opatanol eyedrops; Hcql: hydroxychloroquine; MTX: methotrexate.